Table 4.
Associations between 24-month changes in high-resolution computed tomography and changes in pulmonary function tests from baseline, by treatment group
| Absolute Changes in Quantitative HRCT Scores | Absolute Changes in FVC and DlCO (% predicted) and Dyspnea (TDI) |
|||||
|---|---|---|---|---|---|---|
| Cyclophosphamide (n = 47) |
Mycophenolate mofetil (n = 50) |
|||||
| FVC | DlCO | TDI | FVC | DlCO | TDI | |
| QLF in most severe lobe | −0.55 (P < 0.001) | −0.11 (P = 0.47) | 0.16 (P = 0.36) | −0.46 (P = 0.001) | 0.09 (P = 0.55) | 0.02 (P = 0.91) |
| QLF in whole lung | −0.47 (P < 0.001) | −0.15 (n = 0.34) | −0.27 (P = 0.12) | −0.40 (P = 0.004) | −0.03 (P = 0.85) | −0.03 (P = 0.87) |
| QILD in most severe lobe | −0.47 (P < 0.001) | −0.26 (P = 0.09) | −0.36 (P = 0.03) | −0.42 (P = 0.003) | −0.05 (P = 0.72) | −0.03 (P = 0.88) |
| QILD in whole lung | −0.43 (P = 0.003) | −0.32 (P = 0.04) | −0.42 (P = 0.01) | −0.33 (P = 0.02) | −0.10 (P = 0.49) | −0.07 (P = 0.70) |
| QGG in most severe lobe | −0.02 (P = 0.88) | −0.20 (P = 0.19) | −0.36 (P = 0.03) | −0.07 (P = 0.65) | −0.15 (P = 0.31) | −0.03 (P = 0.86) |
| QGG in whole lung | −0.31 (P = 0.04) | −0.32 (P = 0.03) | −0.48 (P = 0.003) | −0.13 (P = 0.36) | −0.15 (P = 0.31) | −0.01 (P = 0.96) |
Definition of abbreviations: DlCO = diffusing capacity of the lung for carbon monoxide; FVC = forced vital capacity; HRCT = high-resolution computed tomography; QGG = quantitative ground glass; QILD = quantitative interstitial lung disease; QLF = quantitative lung fibrosis; TDI = Transition Dyspnea Index on 7-point scale from −3 (major deterioration) to +3 (major improvement).
Data are presented as Spearman’s ρ (P value). n = 97 pairs for FVC and HRCT; n = 93 pairs for DlCO and HRCT for all patients. For DlCO, n = 44 in cyclophosphamide arm and n = 49 in mycophenolate mofetil arm; for TDI, n = 35 in cyclophosphamide arm and n = 37 in mycophenolate mofetil arm.